A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease.
Gerussi, A., Invernizzi, P. (2019). Better end points needed in primary sclerosing cholangitis trials. NATURE REVIEWS. GASTROENTEROLOGY & HEPATOLOGY, 16(3), 143-144 [10.1038/s41575-019-0110-5].
Better end points needed in primary sclerosing cholangitis trials
Gerussi, A;Invernizzi, P
2019
Abstract
A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
